As one type of long-acting dihydropyridine antihypertensive drug, levamlodipine besylate tablet is the third generation of calcium channel blocker. After successful development of levamlodipine at the end of the 20th century in China, in 1999, the SFDA (currently CFDA) approved the production and launch of the levamlodipine besylate in the market developed by Jilin Shihuida Pharmaceuticals Group. Production of APIs and preparation of levamlodipine of 18 pharmaceutical factories had been approved by December 2014, wherein, 12 for producing of oral tables. The market of levamlodipine of sample hospitals of 22 key cities of China in 2013 had reached 0.278 billion yuan, with the year-on-year growth of 13.93%; levamlodipine ranked the third in Calcium Channel Blocker market, accounting for 15.46% market share, and its market in China had exceeded 1.2 billion yuan, becoming the blockbuster level drug.
As one major variety of Calcium Channel Blocker, is levoisomer of amlodipine, compared to which, levamlodipine has features of good efficacy, small adverse reaction and small dosage. Levamlodipine can spilt the "dextroisomer" that easily results in side effects such as edema and without antihypertensive effect, reserving the levoisomer which has antihypertensive effect.
